article thumbnail

QMS market to value nearly $4b by 2030

European Pharmaceutical Review

According to the research, the pharmaceutical quality management systems market is projected to reach $3.97 billion by 2030. Some pharmaceutical companies are increasing their R&D spending to increase product numbers. Also noted in the report was the shift towards cloud-based systems.

article thumbnail

Formulation development outsourcing market to be worth over $60bn by 2030

European Pharmaceutical Review

billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 Pharmaceutical companies globally are significantly investing in R&D. percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide. percent from its 2022 value of $35.1

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 The rising requirement for small-scale and encapsulated manufacturing processes necessary to assemble these products make it challenging for many pharmaceutical companies to alter their currently installed capacity.

Dosage 98
article thumbnail

Pfizer to reach carbon net-zero by 2040

European Pharmaceutical Review

In the same statement, Pfizer also announced it has signed a pledge by the US Department of Health and Human Services (HHS) that calls on US healthcare system stakeholders such as hospitals, health systems, payers, suppliers and pharmaceutical companies to reduce GHG emissions and build a more climate resilient healthcare infrastructure.

article thumbnail

AI to revolutionise drug development by 2026

European Pharmaceutical Review

Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development , within the next 24-months.

FDA 105
article thumbnail

Biopharmaceuticals contributing to manufacturing outsourcing trend

European Pharmaceutical Review

Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. percent between 2022-2030. The report noted that there has been “considerable” merger and acquisition activity in recent years within the pharmaceutical contract manufacturing market.

article thumbnail

Innovative radioligand manufacturing facility inaugurated

European Pharmaceutical Review

The company hopes to produce this number tenfold by the end of 2030. Radioligand therapy developments in 2023 and 2024 Other companies making progress producing radioligand therapies include Novartis. In January 2024, the pharmaceutical company obtained manufacturing authorisation for its largest radioligand therapy facility.